Skip to main content
. Author manuscript; available in PMC: 2023 Nov 1.
Published in final edited form as: Neurosci Biobehav Rev. 2022 Sep 6;142:104857. doi: 10.1016/j.neubiorev.2022.104857

Table 3.

Efficacy of interventions against Treatment As Usual/Active control.

Age group Setting Outcome Intervention I/G/S Control N of estimates % significance ES type ES (95% CI) Source A / Q
Anorexia Nervosa
ADO OUT GLOBAL FU FBT I ACTIVE 1 100% EFF OR 2.08 (1.07 – 4.03) MA 9 / H
MIX ACCEPT FAM I TAU 1 100% NS RR ns MA 9 / H
FAM I ACTIVE 1 100% NS RR ns MA 9 / H
EDP PT I TAU 1 100% NS g ns MA 10 / H
FAM I ACTIVE 1 100% NS SMD ns MA 9 / H
EDP FU FAM I ACTIVE 1 100% NS SMD ns MA 9 / H
GLOBAL FAM I ACTIVE 1 100% NS RR ns MA 9 / H
GLOBAL FU FAM I ACTIVE 1 100% NS RR ns MA 9 / H
WEIGHT/BODY FAM I ACTIVE 3 33.3% EFF; 66.7% NS SMD ns to 0.44 (0.14 – 0.74) NMA, MA 6 / M
FBT I ACTIVE 2 100% NS SMD ns NMA 6 / M
PT I TAU 1 100% NS g ns MA 10 / H
MULTI I ACTIVE 4 100% NS SMD ns NMA 6 / M
PDO I ACTIVE 1 100% NS SMD ns NMA 6 / M
WEIGHT/BODY FU FAM I ACTIVE 1 100% NS SMD ns MA 9 / H
ADU OUT ACCEPT CBT-ED I TAU 1 100% NS RR ns NMA 10 / H
FBT I TAU 1 100% NS RR ns NMA 10 / H
MANTRA I TAU 1 100% NS RR ns NMA 10 / H
PDO I TAU 1 100% NS RR ns NMA 10 / H
CBT-ED I ACTIVE 1 100% NS RR ns NMA 10 / H
FBT I ACTIVE 1 100% NS RR ns NMA 10 / H
BEHAV CBT-ED I TAU 1 100% NS SMD ns NMA 10 / H
FBT I TAU 1 100% NS SMD ns NMA 10 / H
MANTRA I TAU 1 100% NS SMD ns NMA 10 / H
PDO I TAU 1 100% NS SMD ns NMA 10 / H
CBT-ED I ACTIVE 1 100% NS SMD ns NMA 10 / H
FBT I ACTIVE 1 100% NS SMD ns NMA 10 / H
BEHAV FU CBT-ED I TAU 1 100% NS SMD ns NMA 10 / H
FBT I TAU 1 100% NS SMD ns NMA 10 / H
MANTRA I TAU 1 100% NS SMD ns NMA 10 / H
PDO I TAU 1 100% NS SMD ns NMA 10 / H
CBT-ED I ACTIVE 1 100% NS SMD ns NMA 10 / H
FBT I ACTIVE 1 100% NS SMD ns NMA 10 / H
WEIGHT/BODY CBT-ED I TAU 1 100% NS SMD ns NMA 10 / H
FBT I TAU 1 100% NS SMD ns NMA 10 / H
MANTRA I TAU 1 100% NS SMD ns NMA 10 / H
PDO I TAU 1 100% NS SMD ns NMA 10 / H
CBT-ED I ACTIVE 1 100% NS SMD ns NMA 10 / H
FBT I ACTIVE 1 100% NS SMD ns NMA 10 / H
WEIGHT/BODY FU CBT-ED I TAU 1 100% NS SMD ns NMA 10 / H
FBT I TAU 1 100% NS SMD ns NMA 10 / H
MANTRA I TAU 1 100% NS SMD ns NMA 10 / H
PDO I TAU 1 100% NS SMD ns NMA 10 / H
CBT-ED I ACTIVE 1 100% NS SMD ns NMA 10 / H
FBT I ACTIVE 1 100% NS SMD ns NMA 10 / H
MIX ACCEPT FAM I ACTIVE 1 100% NS RR ns MA 9 / H
EDP FAM I ACTIVE 1 100% NS SMD ns MA 9 / H
PT I TAU 1 100% NS g ns MA 10 / H
EDP FU FAM I ACTIVE 1 100% NS SMD ns MA 9 / H
GLOBAL FAM I TAU 1 100% EFF RR 3.50 (1.49 – 8.23) MA 9 / H
FAM I ACTIVE 2 100% NS RR ns MA 9 / H
GLOBAL FU FAM I ACTIVE 1 100% NS RR ns MA 9 / H
WEIGHT/BODY MULTI I TAU 1 100% NS SMD ns NMA 6 / M
CBT-ED I ACTIVE 3 100% NS SMD ns NMA 6 / M
FAM I ACTIVE 1 100% NS SMD ns MA 9 / H
FBT I ACTIVE 1 100% NS SMD ns NMA 6 / M
IPT I ACTIVE 1 100% NS SMD ns NMA 6 / M
MANTRA I ACTIVE 1 100% NS SMD ns NMA 6 / M
PDO I ACTIVE 2 100% NS SMD ns NMA 6 / M
WEIGHT/BODY FU FAM I ACTIVE 1 100% NS SMD ns MA 9 / H
MIX IN ACCEPT MULTI NA ACTIVE 1 100% DETR RR 0.75 (0.64 – 0.88) MA 9 / H
GENSX MULTI NA ACTIVE 2 100% NS SMD ns MA 9 / H
GLOBAL MULTI NA ACTIVE 1 100% NS RR ns MA 9 / H
WEIGHT/BODY MULTI NA ACTIVE 1 100% NS SMD ns MA 9 / H
OUT ACCEPT CBT-ED I ACTIVE 1 100% NS RR ns MA 9 / H
PDO I TAU 1 100% NS RR ns MA 9 / H
EDP CBT-ED I ACTIVE 1 100% NS SMD ns MA 9 / H
PT I TAU 1 100% NS g ns MA 10 / H
EDP FU CBT-ED I ACTIVE 1 100% NS SMD ns MA 9 / H
F-QOL PT I TAU 1 100% NS g ns MA 10 / H
GLOBAL CBT-ED I ACTIVE 1 100% NS RR ns MA 9 / H
PDO I TAU 1 100% NS RR ns MA 9 / H
WEIGHT/BODY CBT-ED I ACTIVE 1 100% NS MD ns MA 9 / H
PT I TAU 1 100% NS g ns MA 10 / H
WEIGHT/BODY FU CBT-ED I ACTIVE 1 100% NS MD ns MA 9 / H
MIX ACCEPT FBT I ACTIVE 1 100% NS RR ns MA 9 / H
FAM I TAU 1 100% NS RR ns MA 9 / H
EDP CBT-ED I TAU 1 100% NS g ns MA 10 / H
FAM I TAU 2 100% NS SMD ns MA 9.5 / H
PDO I TAU 1 100% NS g ns MA 10 / H
PT I TAU 2 100% NS g ns MA 10 / H
PT G TAU 1 100% NS g ns MA 10 / H
CBT-ED I ACTIVE 1 100% NS g ns MA 6 / M
FAM I ACTIVE 2 100% NS SMD ns MA 9 / H
FBT G ACTIVE 1 100% NS MD ns MA 9 / H
EDP FU CBT-ED I ACTIVE 1 100% NS g ns MA 6 / M
FBT I ACTIVE 2 100% NS SMD ns MA 9 / H
F-QOL CBT-ED I TAU 1 100% NS g ns MA 10 / H
PDO I TAU 1 100% NS g ns MA 10 / H
PT I TAU 1 100% NS g ns MA 10 / H
PT I ACTIVE 1 100% NS g ns MA 10 / H
GLOBAL FBT G ACTIVE 1 100% EFF RR 1.79 (1.20 – 2.63) MA 9 / H
FAM I TAU 2 50% EFF; 50% NS RR ns to 3.83 (1.60 – 9.13) MA 9 / H
FAM I ACTIVE 3 100% NS RR ns MA 9 / H
GLOBAL FU FBT I ACTIVE 3 100% NS RR ns MA 9 / H
WEIGHT/BODY FBT I ACTIVE 5 33.3% EFF; 66.7% NS SMD ns to 0.32 (0.01 – 0.63) MA 9 / H
CBT-ED I TAU 1 100% NS g ns MA 10 / H
EXE I TAU 1 100% NS g ns MA 7 / M
FAM I TAU 1 100% NS g ns MA 10 / H
PDO I TAU 1 100% NS g ns MA 10 / H
PT I TAU 3 100% NS g ns MA 10 / H
PT G TAU 1 100% NS g ns MA 10 / H
PT I ACTIVE 1 100% NS g ns MA 10 / H
WEIGHT/BODY FU FBT I ACTIVE 2 100% NS SMD ns MA 9 / H
Bulimia Nervosa
ADO OUT GLOBAL FU FBT I ACTIVE 1 100% EFF OR 2.22 (1.02 – 4.82) MA 9 / H
MIX BEHAV CBT-ED I ACTIVE 1 100% NS g ns MA 6 / M
EDP CBT-ED I ACTIVE 1 100% NS g ns MA 6 / M
ADU MIX ACCEPT PT I ACTIVE 2 50% EFF; 50% NS RR ns to 1.75 (1.14 – 2.63) MA 8 / H
CBT-ED I ACTIVE 2 100% NS RR ns MA 5 / M
EDU I ACTIVE 1 100% NS RR ns MA 5 / M
PHARMA (AD) I ACTIVE 1 100% NS RR ns MA 8 / H
BEHAV PHARMA (AD) I ACTIVE 1 100% EFF RR 2.08 (1.09 – 25.0) MA 8 / H
CBT-ED I ACTIVE 4 25% EFF; 25% NS; 50% NA* g ns to 0.23 (0.06 – 0.37) MA 5 / M
EDU I ACTIVE 1 100% NS SMD ns MA 5 / M
PT I ACTIVE 2 100% NS SMD ns MA 6.5 / M
EDP CBT-ED I ACTIVE 1 100% EFF g 0.27 (0.08 – 0.45) MA 6 / M
F-QOL CBT-ED I TAU 1 100% NS SMD ns MA 5 / M
GENSX PHARMA (AD) I ACTIVE 1 100% EFF RR 2.13 (1.09 – 100) MA 8 / H
CBT-ED I ACTIVE 2 100% NS SMD ns MA 5 / M
EDU I ACTIVE 1 100% NS SMD ns MA 5 / M
PT I ACTIVE 1 100% NS SMD ns MA 8 / H
GENSX FU EDU I ACTIVE 1 100% NS SMD ns MA 5 / M
GLOBAL CBT-ED I ACTIVE 2 100% EFF OR 1.20 (1.03 – 1.41) to 1.70 (1.21 – 2.38) MA 5.5 / M
PT I ACTIVE 3 66.7% NS; 33.3% DETR RR 0.83 (0.69 – 0.98) to ns NMA, MA 8 / H
BT I ACTIVE 1 100% NS OR ns NMA 8 / H
BT G ACTIVE 1 100% NS OR ns NMA 8 / H
CBT-ED G ACTIVE 1 100% NS OR ns NMA 8 / H
CBT-ED S ACTIVE 2 100% NS OR ns NMA 8 / H
EXE I ACTIVE 1 100% NS OR ns NMA 8 / H
IPT I ACTIVE 1 100% NS OR ns NMA 8 / H
MULTI I ACTIVE 1 100% NS OR ns NMA 8 / H
PHARMA (AD) I ACTIVE 2 100% NS OR ns NMA, MA 8 / H
WEIGHT/BODY CBT-ED I ACTIVE 1 100% NS SMD ns MA 5 / M
MIX OUT ACCEPT PHARMA (AD) I ACTIVE 1 100% DETR RR 0.46 (0.23 – 0.92) MA 7 / M
BEHAV PHARMA (AD) I ACTIVE 1 100% NS SMD ns MA 7 / M
GENSX PHARMA (AD) I ACTIVE 1 100% NS RR ns MA 7 / M
GLOBAL PHARMA (AD) I ACTIVE 1 100% NS RR ns MA 7 / M
MIX ACCEPT PT I ACTIVE 3 66.7% EFF; 33.3% NS RR ns to 1.82 (1.11 – 3.03) MA 10 / H
CBT-ED I ACTIVE 2 100% NS RR ns MA 7 / M
EDU I ACTIVE 1 100% NS RR ns MA 7 / M
PHARMA (AD) I ACTIVE 1 100% NS RR ns MA 10 / H
BEHAV CBT-ED I ACTIVE 12 41.7% EFF; 58.3% NS g ns to 0.42 (0.16 – 0.67) MA 6 / M
CBT-ED I+S ACTIVE 2 50% EFF; 50% NS g ns to 0.30 (0.07 – 0.53) MA 6 / M
CBT-ED G ACTIVE 1 100% NS g ns MA 6 / M
EDU S ACTIVE 1 100% NS SMD ns MA 7 / M
PHARMA (AD) I ACTIVE 1 100% NS SMD ns MA 10 / H
PT I ACTIVE 2 100% NS SMD ns MA 8.5 / H
PT I+S ACTIVE 2 100% NS g ns MA 6 / M
BEHAV FU CBT-ED I ACTIVE 1 100% EFF g 0.31 (0.10 – 0.52) MA 6 / M
EDP CBT-ED I ACTIVE 9 87.8% EFF; 22.2% NS g ns to 0.53 (0.31 – 0.74) MA 6 / M
EDP FU CBT-ED I ACTIVE 1 100% NS g ns MA 6 / M
F-QOL CBT-ED I ACTIVE 1 100% NS SMD ns MA 7 / M
GENSX CBT-ED I ACTIVE 4 25% EFF; 75% NS g ns to 0.25 (0.03 – 0.46) MA 6.5 / M
CBT-ED I+S ACTIVE 1 100% NS g ns MA 6 / M
PHARMA (AD) I ACTIVE 1 100% NS SMD ns MA 10 / H
PT I+S ACTIVE 1 100% NS g ns MA 6 / M
GENSX FU CBT-ED I+S ACTIVE 1 100% NS g ns MA 6 / M
GLOBAL CBT-ED I ACTIVE 7 42.9% EFF; 57.1% NS OR ns to 2.08 (1.23 – 3.53) MA 6 / M
PT I ACTIVE 4 75% NS; 25% DETR RR 0.82 (0.69 – 0.98) to ns MA 10 / H
PHARMA (AD) I ACTIVE 1 100% NS RR ns MA 10 / H
GLOBAL FU CBT-ED I ACTIVE 1 100% NS OR ns MA 6 / M
WEIGHT/BODY CBT-ED I ACTIVE 1 100% NS SMD ns MA 7 / M
Binge Eating Disorder
ADU OUT ACCEPT BT I ACTIVE 1 100% NS RR ns MA 9 / H
ACCEPT FU BT I ACTIVE 1 100% NS RR ns MA 9 / H
BEHAV CBT-ED I ACTIVE 1 100% EFF MD 2.04 (0.35 – 3.73) MA 9 / H
BEHAV FU BT I ACTIVE 1 100% NS MD ns MA 9 / H
WEIGHT/BODY BT I ACTIVE 1 100% NS MD ns MA 9 / H
WEIGHT/BODY FU BT I ACTIVE 1 100% NS MD ns MA 9 / H
MIX ACCEPT PT I ACTIVE 1 100% NS OR ns MA 5 / M
MIX MIX ACCEPT PT I ACTIVE 1 100% EFF OR 5.00 (2.50 – 10.0) MA 9 / H
CBT-ED I ACTIVE 1 100% NS RR ns MA 7 / M
BEHAV BT I ACTIVE 1 100% EFF SMD 0.27 (0.05 – 0.48) MA 9 / H
CBT-ED I ACTIVE 4 50% EFF; 50% NS SMD ns to 0.31 (0.02 – 0.61) MA 6 / M
CBT-ED G ACTIVE 1 100% NS g ns MA 6 / M
CBT-ED S ACTIVE 1 100% NS g ns MA 6 / M
IPT I ACTIVE 1 100% NS SMD ns MA 9 / H
PHARMA (STIM) I ACTIVE 1 100% NS SMD ns NMA 6 / M
PT I ACTIVE 3 100% NS g ns MA 7 / M
BEHAV FU BT I ACTIVE 1 100% DETR SMD −0.24 (−0.46 – −0.01) MA 9 / H
CBT-ED I ACTIVE 1 100% NS g ns MA 6 / M
IPT I ACTIVE 1 100% NS SMD ns MA 9 / H
PT I ACTIVE 1 100% NS SMD ns MA 9 / H
EDP PT I ACTIVE 3 66.7% EFF; 33.3% NS g ns to 0.49 (0.21 – 0.78) MA 7 / M
CBT-ED I ACTIVE 6 16.7% EFF; 83.3% NS g ns to 0.17 (0.01 – 0.33) MA 7 / M
CBT-ED G ACTIVE 1 100% NS g ns MA 6 / M
CBT-ED S ACTIVE 1 100% NS g ns MA 6 / M
PHARMA (STIM) I ACTIVE 1 100% NS SMD ns NMA 6 / M
EDP FU PT I ACTIVE 2 50% EFF; 50% NS g ns to 0.51 (0.19 – 0.83) MA 8 / H
CBT-ED I ACTIVE 1 100% NS g ns MA 6 / M
GENSX BT I ACTIVE 1 100% NS MD ns MA 9 / H
CBT-ED I ACTIVE 1 100% NS g ns MA 8 / H
PT I ACTIVE 3 100% NS g ns MA 7 / M
GENSX FU BT I ACTIVE 1 100% NS MD ns MA 9 / H
PT I ACTIVE 3 100% NS g ns MA 7 / M
GLOBAL PHARMA (STIM) I ACTIVE 1 100% EFF RR 1.56 (1.06 – 2.29) NMA 6 / M
BT G ACTIVE 1 100% NS RD ns MA 9 / H
CBT-ED I ACTIVE 3 100% NS OR ns MA 6 / M
CBT-ED G ACTIVE 1 100% NS OR ns MA 6 / M
CBT-ED S ACTIVE 1 100% NS OR ns MA 6 / M
IPT I ACTIVE 1 100% NS RD ns MA 9 / H
PT I ACTIVE 3 100% NS OR ns MA 7 / M
GLOBAL FU BT G ACTIVE 1 100% DETR RD −0.13 (−0.25 – −0.02) MA 9 / H
CBT-ED I ACTIVE 1 100% NS OR ns MA 6 / M
IPT I ACTIVE 1 100% NS RD ns MA 9 / H
PT I ACTIVE 1 100% NS OR ns MA 9 / H
WEIGHT/BODY PT I ACTIVE 2 50% NS; 50% DETR MD −0.46 (−0.94 – −0.07) to ns MA 9 / H
BT I ACTIVE 1 100% NS SMD ns MA 9 / H
CBT-ED I ACTIVE 1 100% NS SMD ns MA 7 / M
IPT I ACTIVE 1 100% NS MD ns MA 9 / H
WEIGHT/BODY FU BT I ACTIVE 1 100% NS SMD ns MA 9 / H
IPT I ACTIVE 1 100% NS MD ns MA 9 / H
PT I ACTIVE 1 100% NS SMD ns MA 9 / H
Mixed Eating Disorders
ADO OUT GLOBAL FBT I ACTIVE 3 33.3% EFF; 66.7% NS OR ns to 2.14 (1.29 – 3.53) MA 9 / H
GLOBAL FU FBT I ACTIVE 1 100% EFF OR 2.35 (1.33 – 4.14) MA 9 / H
ADU MIX ACCEPT CBT-ED I ACTIVE 1 100% NS RR ns MA 5 / M
CBT-ED S ACTIVE 1 100% NS RR ns MA 5 / M
PHARMA (MIX) I ACTIVE 1 100% NS OR ns MA 5 / M
PT I ACTIVE 1 100% NS OR ns MA 5 / M
BEHAV CBT-ED S ACTIVE 1 100% EFF SMD 0.42 (0.09 – 0.76) MA 5 / M
CBT-ED I ACTIVE 2 50% EFF; 50% NS SMD ns to 0.19 (0.05 – 0.33) MA 5 / M
F-QOL CBT-ED I ACTIVE 1 100% NS SMD ns MA 5 / M
GENSX CBT-ED I ACTIVE 2 50% EFF; 50% NS SMD ns to 0.49 (0.01 – 0.97) MA 5 / M
CBT-ED S ACTIVE 2 100% NS SMD ns MA 5 / M
GLOBAL CBT-ED I ACTIVE 1 100% EFF RR 1.23 (1.09 – 1.39) MA 5 / M
CBT-ED S ACTIVE 1 100% NS RR ns MA 5 / M
WEIGHT/BODY CBT-ED I ACTIVE 2 100% NS SMD ns MA 5 / M
CBT-ED S ACTIVE 1 100% NS SMD ns MA 5 / M
MIX OUT BEHAV VR-CBT-ED I ACTIVE 2 50% EFF; 50% NS MD ns to 0.29 (0.01 – 0.57) MA 7 / M
MIX ACCEPT CBT-ED I ACTIVE 1 100% NS RR ns MA 7 / M
CBT-ED S ACTIVE 1 100% NS RR ns MA 7 / M
EDU S ACTIVE 5 100% NS RR ns MA 9 / H
MULTI S ACTIVE 2 100% NS RR ns MA 9 / H
BEHAV CBT-ED S ACTIVE 1 100% EFF SMD 0.42 (0.09 – 0.76) MA 7 / M
e-PT I ACTIVE 1 100% EFF g 0.28 (0.07 – 0.51) MA 7 / M
CBT-ED I ACTIVE 4 50% EFF; 50% NS g ns to 0.29 (0.09 – 0.49) MA 8.5 / H
PT I ACTIVE 5 20% EFF; 80% NS SMD ns to 0.19 (0.05 – 0.33) MA 9 / H
IPT I ACTIVE 1 100% DETR g −0.22 (−0.39 – −0.05) MA 10 / H
EDU S ACTIVE 9 100% NS RR ns MA 9 / H
PT G ACTIVE 2 100% NS g ns MA 9 / H
BEHAV FU CBT-ED I ACTIVE 3 100% NS RR ns MA 9 / H
CBT-ED G ACTIVE 1 100% NS RR ns MA 9 / H
EDU S ACTIVE 2 100% NS RR ns MA 9 / H
PT I ACTIVE 3 100% NS RR ns MA 9 / H
EDP CBT-ED I ACTIVE 9 100% EFF g 0.18 (0.01 – 0.35) to 0.37 (0.18 – 0.56) MA 8 / H
MULTI I ACTIVE 2 50% EFF; 50% NS SMD ns to 0.72 (0.25 – 1.20) MA 7 / M
IPT I ACTIVE 4 50% EFF; 50% NS g ns to 0.56 (0.27 – 0.85) MA 10 / H
CBT-ED S ACTIVE 3 66.7% EFF; 33.3% NS g ns to 0.39 (0.14 – 0.65) MA 8 / H
PT I ACTIVE 11 9.1% EFF; 91.9% NS g ns to 0.17 (0.03 – 0.32) MA 7 / M
CBT-ED G ACTIVE 1 100% NS g ns MA 9 / H
EDU S ACTIVE 2 100% NS SMD ns MA 9 / H
PT G ACTIVE 1 100% NS g ns MA 9 / H
EDP FU PT I ACTIVE 6 16.7% EFF; 83.3% NS g ns to 0.92 (0.71 – 1.21) MA 7 / M
CBT-ED I ACTIVE 3 66.7% EFF; 33.3% NS g ns to 0.33 (0.05 – 0.62) MA 9 / H
CBT-ED G ACTIVE 1 100% NS g ns MA 9 / H
EDU S ACTIVE 1 100% NS MD ns MA 9 / H
F-QOL CBT-ED I ACTIVE 2 100% NS SMD ns MA 8 / H
F-QOL FU CBT-ED I ACTIVE 1 100% NS g ns MA 9 / H
GENSX CBT-ED I ACTIVE 4 100% NS SMD ns MA 8 / H
CBT-ED S ACTIVE 2 100% NS SMD ns MA 7 / M
EDU S ACTIVE 5 100% NS SMD ns MA 9 / H
PT I ACTIVE 4 100% NS g ns MA 8 / H
GENSX FU CBT-ED I ACTIVE 2 100% NS g ns MA 9 / H
EDU S ACTIVE 2 100% NS SMD ns MA 8 / H
PT I ACTIVE 5 100% NS g ns MA 7 / M
GLOBAL CBT-ED I ACTIVE 1 100% NS RR ns MA 7 / M
CBT-ED S ACTIVE 1 100% NS RR ns MA 7 / M
IPT I ACTIVE 1 100% NS g ns MA 10 / H
PT I ACTIVE 1 100% NS RR ns MA 7 / M
GLOBAL FU CBT-ED I ACTIVE 1 100% NS OR ns MA 6 / M
PT I ACTIVE 1 100% NS RR ns MA 6 / M
WEIGHT/BODY CBT-ED I ACTIVE 1 100% EFF SMD 0.18 (0.01 – 0.34) MA 7 / M
CBT-ED S ACTIVE 1 100% NS SMD ns MA 7 / M
EDU S ACTIVE 1 100% NS WMD ns MA 9 / H
IPT I ACTIVE 1 100% NS g ns MA 10 / H
MULTI I ACTIVE 1 100% NS MD ns MA 10 / H
*,

unclear from the MA if the effect size was significant or not;

A, quality as per AMSTAR 0–11 score (median if >1 comparison); ACCEPT, acceptability; AD, antidepressants; ADU, adults; BEHAV, behavioural symptoms; BT, behavioural therapy; CBT-ED, cognitive behavioural therapy for eating disorders; eCBT-ED, electronic/virtual CBT-ED; CI, confidence interval; DETR, statistically significant difference that favours control; EDP, eating disorder psychopathology; EDU, psychoeducation; EFF, statistically significant difference that favours intervention; ES, effect size; EXE, guided physical exercise; F-QOL, functioning/quality of life; FAM, mixed family interventions; FBT, family-based therapy; FU, at follow up; G, group intervention; g, Hedges’ g; GENSX, psychiatric general symptoms; GLOBAL, improvement/response/remission/relapse; I, individual intervention; IPT, interpersonal psychotherapy; MANTRA, Maudsley Anorexia Treatment for Adults; MD, mean difference; MIX, mixed or not specified age group/setting/medications; MULTI, mixed active interventions; NA, not assessed; NS/ns, no statistically significant difference; Q, quality level (L=low-AMSTAR <4, M=medium-AMSTAR 4 to 7, H=high-AMSTAR >7); OR, odds ratio; OUT, outpatient; PDO, psychodynamic-oriented psychotherapy; PHARMA, pharmacological intervention; PT, psychotherapy; RD, risk difference; RR, risk ratio; S, self-help intervention; SMD, standardized mean difference; STIM, psychostimulants; VR-CBT-ED, CBT-ED plus virtual reality; TAU, treatment as usual; WEIGHT/BODY, changes in weight/BMI/body composition; WMD, weighted mean difference.

Significant results are presented in bold. Results are ordered as significant ones first, ordered by ES magnitude and % significant comparisons, and then non- significant ones in alphabetical order.